Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play

Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?  

Build out
Pharma is building digital pathology capacity • Source: Shutterstock

Large pharmaceutical companies are eager to talk about their digital transformation and their whole-hearted adoption of computational biology and artificial intelligence (AI). In the same vein, many are enthusiastically emphasizing the contributions digital pathology is making throughout their R&D organizations.

Digital pathology is helping pharma across the spectrum of drug discovery and development. (See Exhibit 1.) The technology digitizes hematoxylin...

More from Innovation

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By 

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

More from In Vivo